Alexandria Pharmaceuticals results, Q2 2022
Net profit, assets, equity and cash flow for Q2 2022, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit24.08 millionEGP
Total assets876 millionEGP
Shareholders' equity577 millionEGP
Operating cash flow46.44 millionEGP
In short
- Alexandria Pharmaceuticals's net profit for Q2 2022 was about 24.08 million EGP.
- Total assets at the end of Q2 2022 were about 876 million EGP, and shareholders' equity about 577 million EGP.
- Operating cash flow for Q2 2022 was positive at 46.44 million EGP.
Key lines against the same period a year earlier
This periodYear earlierChange
Net profit24.08 million——
Gross profit60.69 million——
Total assets876 million——
Total liabilities300 million——
Shareholders' equity577 million——
Total liabilities and equity876 million——
Operating cash flow46.44 million——
Investing cash flow-6.82 million——
Financing cash flow-33.23 million——
Net change in cash6.39 million——
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Alexandria Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy